Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Public ClinicalTrials.gov record NCT00855595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea
Study identification
- NCT ID
- NCT00855595
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- LEO Pharma
- Industry
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Interventions
- Azelaic acid (Finacea, BAY39-6251) Drug
- Metronidazole (Metrogel) Drug
- Doxycycline (Oracea) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Mar 31, 2009
- Completion
- Jun 30, 2009
- Last update posted
- Mar 30, 2020
2009
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Denver | Colorado | 80209 | — |
| Not listed | West Palm Beach | Florida | 33401 | — |
| Not listed | Boston | Massachusetts | 02114-2517 | — |
| Not listed | Warren | Michigan | 48088 | — |
| Not listed | Fridley | Minnesota | 55432 | — |
| Not listed | Henderson | Nevada | 89052 | — |
| Not listed | Albuquerque | New Mexico | 87106 | — |
| Not listed | Stony Brook | New York | 11790 | — |
| Not listed | Mason | Ohio | 45040 | — |
| Not listed | Portland | Oregon | 97223 | — |
| Not listed | Austin | Texas | 78759 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Houston | Texas | 77056 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Salt Lake City | Utah | 84124 | — |
| Not listed | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00855595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00855595 live on ClinicalTrials.gov.